MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Tissue Engineering _ Stem Cells
Cytori Therapeutics (NASDAQ:CYTX)
Organization & Developments: Cytori
Parents
Cytori Therapeutics (NASDAQ:CYTX)
Children
2019: However, Cytori eventually failed in that mission and recently sold off most of its stem cell assets as a lack of clinical success, a debt burden, and a pair of reverse splits have destroyed virtually all shareholder value.
2019: Cytori Therapeutics (CYTX), an early leader, tried to succeed with the autologous model using adipose as a source or adipose derived regenerative cells.
A clinical trial of patients with chronic cardiac ischemia has had positive outcomes as well, with patients demonstrating improv
A study published in 2009 in the Journal of the American College of Cardiology found that adult stem cells may help repair heart
Adult stem and regenerative cells have been shown to promote healing.
All Natural: Why Breasts Are the Key to the Future of Regenerative Medicine
Cytori is conducting its own study of the Celution System to treat heart attack patients.
Cytori is working with the U.S. Food and Drug Administration to begin conducting clinical trials of the Celution System in the U
Cytori operates within what is expected to be a high-demand sector in the coming years: The market for regenerative medicine cou
Cytori’s lead product is the Celution System, a medical device that extracts and separates stem and regenerative cells from a pa
In May, the company announced that patients had experienced a substantial reduction in heart damage, as well as improved blood s
Specializes in products designed for the extraction of stem and regenerative cells from adipose (fat) tissue.
The company is currently conducting a 70-patient European study of the Celution System for breast cancer patients, with final da
The company is exploring other applications of its Celution technology, including cardiovascular disease, urinary incontinence,
The device is currently approved in Europe for applications including breast reconstruction, soft tissue repair, and the facilit
Within 24 hours of the heart attack, the patient’s adipose-derived stem and regenerative cells are extracted and injected into t
Jumps
*Key People: Cytori
Finance & Acquisitions: Cytori